SCHEMBL2097539

SCHEMBL2097539

CCCCCCCCCOc1ccccc1NC(=O)OC

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EBP Q15125 1/20 0.65
SIGMAR1 Q99720 1/20 0.65
KMT2A Q03164 2/20 0.59
PTPN1 P18031 3/20 0.58
POLB P06746 1/20 0.55
TSHR P16473 1/20 0.55
LMNA P02545 2/20 0.55
MAPT P10636 2/20 0.55
MEN1 O00255 1/20 0.55
NR1I2 O75469 1/20 0.55
CHRM2 P08172 1/20 0.55
CYP3A4 P08684 1/20 0.55
ADRA2A P08913 1/20 0.55
OPRK1 P41145 1/20 0.55
HTR2B P41595 1/20 0.55
SLC6A3 Q01959 1/20 0.55
HDAC6 Q9UBN7 1/20 0.55
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
GAA P10253 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10457597 0.89 NPC1 (0.65) EBPSIGMAR1KMT2APOLBTSHR
SCHEMBL2097538 0.89 EBP (0.62) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL11482525 0.87 KMT2A (0.64) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL8930342 0.87 MAPT (0.64) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL7952997 0.87 KMT2A (0.64) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL14625066 0.87 KMT2A (0.64) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL8930340 0.85 KMT2A (0.59) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL7952996 0.85 KMT2A (0.59) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL11482522 0.85 KMT2A (0.59) EBPSIGMAR1KMT2APTPN1POLB
SCHEMBL18554186 0.85 KMT2A (0.62) EBPSIGMAR1KMT2APTPN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 EBP 1409/4885SIGMAR1 161/4885KMT2A 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.